FIND

researchers

DISCOVER

relevant articles

PROMOTE

your research

now for free

Thomas Lynch

Research Profile

Disorders

Procedures

Chemicals & Drugs

Concepts & Ideas

Physiology

Activities & Behaviors

Smoking

Co-author Network

Publications

TOP 3
Noah C Choi; Tristen T Chun; Panos M Fidias; Richard L Kradin; Thomas J Lynch; Douglas J Mathisen; Andrzej Niemierko; Marek Ancukiewicz; Alan J Fischman
Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.
Jennifer S Temel; Sonal Admane; Constance Dahlin; Emily R Gallagher; Joseph A Greer; Vicki A Jackson; Inga T Lennes; Thomas J Lynch; William F Pirl
Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care.
Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.

Register for free to view:

Visualized networks:

See your personal network in
sophisticated graphical views

GeoTargeted Searches:

Locate experts around the world
and connect with global collaborators

Research Profiles:

See the research activity
of experts around the globe

Geonetwork of Thomas Lynch (preview)

Cities where this author has publications
Cities where co-authors of this author have publications

Flash Player Required

All Publications

2013: Noah C Choi; Tristen T Chun; Panos M Fidias; Richard L Kradin; Thomas J Lynch; Douglas J Mathisen; Andrzej Niemierko; Marek Ancukiewicz; Alan J Fischman
Potential of (18)F-FDG PET toward personalized radiotherapy or chemoradiotherapy in lung cancer.
European journal of nuclear medicine and molecular imaging 2013;40(6):832-41.
2011: Jennifer S Temel; Sonal Admane; Constance Dahlin; Emily R Gallagher; Joseph A Greer; Vicki A Jackson; Inga T Lennes; Thomas J Lynch; William F Pirl
Longitudinal perceptions of prognosis and goals of therapy in patients with metastatic non-small-cell lung cancer: results of a randomized study of early palliative care.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2011;29(17):2319-26.
2011: Lecia V Sequist; Belinda A Waltman; Dora Dias-Santagata; Subba Digumarthy; Alexa B Turke; Panos Fidias; Kristin Bergethon; Alice T Shaw; Scott Gettinger; Arjola K Cosper; Sara Akhavanfard; Rebecca S Heist; Jennifer Temel; James G Christensen; John C Wain; Thomas J Lynch; Kathy Vernovsky; Eugene J Mark; Michael Lanuti; A John Iafrate; Mari Mino-Kenudson; Jeffrey A Engelman
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors.
Science translational medicine 2011;3(75):75ra26.
2010: April F Eichler; Kristopher T Kahle; Daphne L Wang; Victoria A Joshi; Henning Willers; Jeffrey A Engelman; Thomas J Lynch; Lecia V Sequist
EGFR mutation status and survival after diagnosis of brain metastasis in nonsmall cell lung cancer.
Neuro-oncology 2010;12(11):1193-9.
2010: Lecia V Sequist; Benjamin Besse; Thomas J Lynch; Vincent A Miller; Kwok K Wong; Barbara Gitlitz; Keith Eaton; Charles Zacharchuk; Amy Freyman; Christine Powell; Revathi Ananthakrishnan; Susan Quinn; Jean-Charles Soria
Neratinib, an irreversible pan-ErbB receptor tyrosine kinase inhibitor: results of a phase II trial in patients with advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2010;28(18):3076-83.
2010: Dora Dias-Santagata; Sara Akhavanfard; Serena S David; Kathy Vernovsky; Georgiana Kuhlmann; Susan L Boisvert; Hannah Stubbs; Ultan McDermott; Jeffrey Settleman; Eunice L Kwak; Jeffrey W Clark; Steven J Isakoff; Lecia V Sequist; Jeffrey A Engelman; Thomas J Lynch; Daniel A Haber; David N Louis; Leif W Ellisen; Darrell R Borger; A John Iafrate
Rapid targeted mutational analysis of human tumours: a clinical platform to guide personalized cancer medicine.
EMBO molecular medicine 2010;2(5):146-58.
2009: Lecia V Sequist; Panos M Fidias; Jennifer S Temel; Tatjana Kolevska; Michael S Rabin; Ralph V Boccia; Howard A Burris; Robert J Belt; Mark S Huberman; Ostap Melnyk; Glenn M Mills; Craig W Englund; David C Caldwell; James G Keck; Lisa Meng; Marsha Jones; Gail L Brown; Martin J Edelman; Thomas J Lynch
Phase 1-2a multicenter dose-ranging study of canfosfamide in combination with carboplatin and paclitaxel as first-line therapy for patients with advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(11):1389-96.
2009: Alice T Shaw; Beow Y Yeap; Mari Mino-Kenudson; Subba R Digumarthy; Daniel B Costa; C. Rebecca Suk Heist; Benjamin Solomon; Hannah Stubbs; Sonal Admane; Ultan McDermott; Jeffrey Settleman; Susumu Kobayashi; Eugene J Mark; Scott J Rodig; Lucian R Chirieac; Eunice L Kwak; Thomas J Lynch; A John Iafrate
Clinical features and outcome of patients with non-small-cell lung cancer who harbor EML4-ALK.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(26):4247-53.
2009: Inga T Lennes; Thomas J Lynch
Quality indicators in cancer care: development and implementation for improved health outcomes in non-small-cell lung cancer.
Clinical lung cancer 2009;10(5):341-6.
2009: William Pao; Mark G Kris; A John Iafrate; Marc Ladanyi; Pasi A Janne; Ignacio I Wistuba; Ryn Miake-Lye; Roy S Herbst; David P Carbone; Bruce E Johnson; Thomas J Lynch
Integration of molecular profiling into the lung cancer clinic.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(17):5317-22.
2009: Lecia V Sequist; Panos Fidias; C. Rebecca Suk Heist; Patricia Ostler; Alona Muzikansky; Thomas J Lynch
Brief report of biweekly pemetrexed and gemcitabine in elderly patients with non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(9):1170-3.
2009: Panos Fidias; Nathan A Pennell; Anthony L Boral; Geoffrey I Shapiro; Arthur T Skarin; Joseph P Eder; T Jesse Kwoh; Richard S Geary; Bruce E Johnson; Thomas J Lynch; Jeffrey G Supko
Phase I study of the c-raf-1 antisense oligonucleotide ISIS 5132 in combination with carboplatin and paclitaxel in patients with previously untreated, advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(9):1156-62.
2009: Scott J Rodig; Mari Mino-Kenudson; Sanja Dacic; Beow Y Yeap; Alice Shaw; Justine A Barletta; Hannah Stubbs; Kenny Law; Neal Lindeman; Eugene Mark; Pasi A Janne; Thomas J Lynch; Bruce E Johnson; A John Iafrate; Lucian R Chirieac
Unique clinicopathologic features characterize ALK-rearranged lung adenocarcinoma in the western population.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(16):5216-23.
2009: William F Pirl; Jessica Solis; Joseph Greer; Lecia Sequist; Jennifer S Temel; Thomas J Lynch
Epidermal growth factor receptor tyrosine kinase inhibitors and depression.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(23):e49-50; author reply e51.
2009: Thomas J Lynch; David Fenton; Vera Hirsh; David Bodkin; Edward L Middleman; Alberto Chiappori; Balazs Halmos; Reyna Favis; Hua Liu; William L Trepicchio; Omar Eton; Frances A Shepherd
A randomized phase 2 study of erlotinib alone and in combination with bortezomib in previously treated advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(8):1002-9.
2009: Penelope A Bradbury; Matthew H Kulke; C. Rebecca Suk Heist; Wei Zhou; Clement Ma; Wei Xu; Ariela L Marshall; Rihong Zhai; Susanne M Hooshmand; Kofi Asomaning; Li Su; Frances A Shepherd; Thomas J Lynch; John C Wain; David C Christiani; Geoffrey Liu
Cisplatin pharmacogenetics, DNA repair polymorphisms, and esophageal cancer outcomes.
Pharmacogenetics and genomics 2009;19(8):613-25.
2009: Penelope A Bradbury; Rihong Zhai; Clement Ma; Wei Xu; Jessica Hopkins; Matthew J Kulke; Kofi Asomaning; Zhaoxi Wang; Li Su; C. Rebecca Suk Heist; Thomas J Lynch; John C Wain; David Christiani; Geoffrey Liu
Vascular endothelial growth factor polymorphisms and esophageal cancer prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(14):4680-5.
2009: Lecia V Sequist; Jeffrey A Engelman; Thomas J Lynch
Toward noninvasive genomic screening of lung cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(16):2589-91.
2009: David W Cescon; Penelope A Bradbury; Kofi Asomaning; Jessica Hopkins; Rihong Zhai; Wei Zhou; Zhaoxi Wang; Matthew Kulke; Li Su; Clement Ma; Wei Xu; Ariela L Marshall; C. Rebecca Suk Heist; John C Wain; Thomas J Lynch; David C Christiani; Geoffrey Liu
p53 Arg72Pro and MDM2 T309G polymorphisms, histology, and esophageal cancer prognosis.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(9):3103-9.
2009: Rebecca A Miksad; Mithat Gonen; Thomas J Lynch; Thomas G Roberts
Interpreting trial results in light of conflicting evidence: a Bayesian analysis of adjuvant chemotherapy for non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2009;27(13):2245-52.
2009: Jennifer S Temel; Joseph A Greer; Sarah Goldberg; Paula Downes Vogel; Michael Sullivan; William F Pirl; Thomas J Lynch; David C Christiani; Matthew R Smith
A structured exercise program for patients with advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(5):595-601.
2009: Nathan A Pennell; Thomas J Lynch
Combined inhibition of the VEGFR and EGFR signaling pathways in the treatment of NSCLC.
The oncologist 2009;14(4):399-411.
2009: Kwok-K Wong; Paula M Fracasso; Ronald M Bukowski; Thomas J Lynch; Pamela N Munster; Geoffrey I Shapiro; Pasi A Janne; Joseph P Eder; Michael J Naughton; Matthew J Ellis; Suzanne F Jones; Tarek Mekhail; Charles Zacharchuk; Jennifer Vermette; Richat Abbas; Susan Quinn; Christine Powell; Howard A Burris
A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(7):2552-8.
2009: Lecia V Sequist; Sunitha Nagrath; Mehmet Toner; Daniel A Haber; Thomas J Lynch
The CTC-chip: an exciting new tool to detect circulating tumor cells in lung cancer patients.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2009;4(3):281-3.
2009: Roy S Herbst; Thomas J Lynch; Alan B Sandler
Beyond doublet chemotherapy for advanced non-small-cell lung cancer: combination of targeted agents with first-line chemotherapy.
Clinical lung cancer 2009;10(1):20-7.
2009: Andrew X Zhu; Neal Ready; jeffrey clark; Howard Safran; Antonino Amato; Nadia Salem; Silvia Pace; Xiaoying He; Nela Zvereva; Thomas J Lynch; David P Ryan; Jeffrey G Supko
Phase I and pharmacokinetic study of gimatecan given orally once a week for 3 of 4 weeks in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2009;15(1):374-81.
2008: Joseph A Greer; William F Pirl; Elyse R Park; Thomas J Lynch; Jennifer S Temel
Behavioral and psychological predictors of chemotherapy adherence in patients with advanced non-small cell lung cancer.
Journal of psychosomatic research 2008;65(6):549-52.
2008: C. Rebecca Suk Heist; Wei Zhou; Zhaoxi Wang; Geoffrey Liu; Donna Neuberg; Li Su; Kofi Asomaning; Bruce W Hollis; Thomas J Lynch; John C Wain; Edward Giovannucci; David C Christiani
Circulating 25-hydroxyvitamin D, VDR polymorphisms, and survival in advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(34):5596-602.
2008: Rihong Zhai; Geoffrey Liu; Kofi Asomaning; Li Su; Matthew H Kulke; C. Rebecca Suk Heist; Norman S Nishioka; Thomas J Lynch; John C Wain; Xihong Lin; David C Christiani
Genetic polymorphisms of VEGF, interactions with cigarette smoking exposure and esophageal adenocarcinoma risk.
Carcinogenesis 2008;29(12):2330-4.
2008: Darren Tse; Rihong Zhai; Wei Zhou; C. Rebecca Suk Heist; Kofi Asomaning; Li Su; Thomas J Lynch; John C Wain; David C Christiani; Geoffrey Liu
Polymorphisms of the NER pathway genes, ERCC1 and XPD are associated with esophageal adenocarcinoma risk.
Cancer causes & control : CCC 2008;19(10):1077-83.
2008: Lidia Schapira; Leah Gordon-Rowe; Rosalba Martignetti; Deborah Washington; Mimi Bartholomay; Donna Greenberg; Christopher Lathan; Joanne LaFrancesca; Thomas J Lynch; Bruce A Chabner
Racism in the chemotherapy infusion unit: a nurse's story.
The oncologist 2008;13(11):1177-80.
2008: Tan Min Chin; Margaret P Quinlan; Anurag Singh; Lecia V Sequist; Thomas J Lynch; Daniel A Haber; Sreenath V Sharma; Jeffrey Settleman
Reduced Erlotinib sensitivity of epidermal growth factor receptor-mutant non-small cell lung cancer following cisplatin exposure: a cell culture model of second-line erlotinib treatment.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(21):6867-76.
2008: Thomas E Stinchcombe; Ann M Mauer; Lydia D Hodgson; James E Herndon; Thomas J Lynch; Mark R Green; Everett E Vokes
Phase II trial of paclitaxel and cisplatin in patients with extensive stage small cell lung cancer: Cancer and Leukemia Group B Trial 9430.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(11):1301-7.
2008: Monica Ter-Minassian; Rihong Zhai; Kofi Asomaning; Li Su; Wei Zhou; Geoffrey Liu; C. Rebecca Suk Heist; Thomas J Lynch; John C Wain; Xihong Lin; Immaculata De Vivo; David C Christiani
Apoptosis gene polymorphisms, age, smoking and the risk of non-small cell lung cancer.
Carcinogenesis 2008;29(11):2147-52.
2008: C. Rebecca Suk Heist; Panos Fidias; Mark Huberman; Blair Ardman; Lecia V Sequist; Jennifer S Temel; Thomas J Lynch
A phase II study of oxaliplatin, pemetrexed, and bevacizumab in previously treated advanced non-small cell lung cancer.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(10):1153-8.
2008: Akash Nanda; Dora C Dias-Santagata; Hannah Stubbs; Carl J O'Hara; Ken S Zaner; Thomas J Lynch; Henning Willers
Unusual tumor response and toxicity from radiation and concurrent erlotinib for non-small-cell lung cancer.
Clinical lung cancer 2008;9(5):285-7.
2008: Jennifer S Temel; Jessica McCannon; Joseph A Greer; Vicki A Jackson; Patricia Ostler; William F Pirl; Thomas J Lynch; J Andrew Billings
Aggressiveness of care in a prospective cohort of patients with advanced NSCLC.
Cancer 2008;113(4):826-33.
2008: Shyamala Maheswaran; Lecia V Sequist; Sunitha Nagrath; Lindsey Ulkus; Brian Brannigan; Chey V Collura; Elizabeth Inserra; Sven Diederichs; A John Iafrate; Daphne W Bell; Subba R Digumarthy; Alona Muzikansky; daniel irimia; Jeffrey Settleman; Ronald G Tompkins; Thomas J Lynch; Mehmet Toner; Daniel A Haber
Detection of mutations in EGFR in circulating lung-cancer cells.
The New England journal of medicine 2008;359(4):366-77.
2008: Kofi Asomaning; David P Miller; Geoffrey Liu; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Second hand smoke, age of exposure and lung cancer risk.
Lung cancer (Amsterdam, Netherlands) 2008;61(1):13-20.
2008: Thomas J Lynch; George R Blumenschein; Jeffrey A Engelman; Igor Espinoza-Delgado; Ramaswamy Govindan; Jeff Hanke; Nasser H Hanna; John V Heymach; Fred R Hirsch; Pasi A Janne; Rogerio Lilenbaum; Ronald B Natale; Gregory J Riely; Lecia V Sequist; Geoffrey I Shapiro; Alice Shaw; Frances A Shepherd; Mark A Socinski; A Gregory Sorensen; Heather A Wakelee; Aaron Weitzman
Summary statement novel agents in the treatment of lung cancer: Fifth Cambridge Conference assessing opportunities for combination therapy.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2008;3(6 Suppl 2):S107-12.
2008: Lecia V Sequist; Renato G Martins; David Spigel; Steven M Grunberg; Alexander Spira; Pasi A Janne; Victoria A Joshi; David McCollum; Tracey L Evans; Alona Muzikansky; Georgiana L Kuhlmann; Moon Han; Jonathan S Goldberg; Jeffrey Settleman; A John Iafrate; Jeffrey A Engelman; Daniel A Haber; Bruce E Johnson; Thomas J Lynch
First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(15):2442-9.
2008: Lidia Schapira; Erika Vargas; Renzo Hidalgo; Marilyn Brier; Lourdes Sanchez; Karin Hobrecker; Thomas J Lynch; Bruce A Chabner
Lost in translation: integrating medical interpreters into the multidisciplinary team.
The oncologist 2008;13(5):586-92.
2008: William F Pirl; Jennifer S Temel; Andrew Billings; Constance Dahlin; Vicki Jackson; Holly G Prigerson; Joseph Greer; Thomas J Lynch
Depression after diagnosis of advanced non-small cell lung cancer and survival: a pilot study.
Psychosomatics 2008;49(3):218-24.
2008: Geoffrey Liu; Sarada Gurubhagavatula; Wei Zhou; Z Wang; Beow Y Yeap; K Asomaning; Li Su; C. Rebecca Suk Heist; Thomas J Lynch; David C Christiani
Epidermal growth factor receptor polymorphisms and clinical outcomes in non-small-cell lung cancer patients treated with gefitinib.
The pharmacogenomics journal 2008;8(2):129-38.
2008: Nathan A Pennell; Gilbert H Daniels; Robert I Haddad; Douglas S Ross; Tracey Evans; Lori J Wirth; Panos H Fidias; Jennifer S Temel; Sarada Gurubhagavatula; C. Rebecca Suk Heist; John R Clark; Thomas J Lynch
A phase II study of gefitinib in patients with advanced thyroid cancer.
Thyroid : official journal of the American Thyroid Association 2008;18(3):317-23.
2008: M Früh; Wei Zhou; Rihong Zhai; Li Su; C. Rebecca Suk Heist; John C Wain; N S Nishioka; Thomas J Lynch; Frances A Shepherd; David C Christiani; Geoffrey Liu
Polymorphisms of inflammatory and metalloproteinase genes, Helicobacter pylori infection and the risk of oesophageal adenocarcinoma.
British journal of cancer 2008;98(4):689-92.
2008: C. Rebecca Suk Heist; Rihong Zhai; Geoffrey Liu; Wei Zhou; Xihong Lin; Li Su; Kofi Asomaning; Thomas J Lynch; John C Wain; David C Christiani
VEGF polymorphisms and survival in early-stage non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2008;26(6):856-62.
2008: Geoffrey Liu; Paul Wheatley-Price; Wei Zhou; Sohee Park; C. Rebecca Suk Heist; Kofi Asomaning; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Genetic polymorphisms of MDM2, cumulative cigarette smoking and nonsmall cell lung cancer risk.
International journal of cancer. Journal international du cancer 2008;122(4):915-8.
2008: Cameron D Wright; Noah C Choi; John C Wain; Douglas J Mathisen; Thomas J Lynch; Panos Fidias
Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage III and IVA thymic tumors.
The Annals of thoracic surgery 2008;85(2):385-9.
2008: Rihong Zhai; Geoffrey Liu; Wei Zhou; Li Su; C. Rebecca Suk Heist; Thomas J Lynch; John C Wain; Kofi Asomaning; Xihong Lin; David C Christiani
Vascular endothelial growth factor genotypes, haplotypes, gender, and the risk of non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2008;14(2):612-7.
2008: Penelope A Bradbury; C. Rebecca Suk Heist; Matthew H Kulke; Wei Zhou; Ariela L Marshall; David P Miller; Li Su; Sohee Park; Jennifer S Temel; Panos Fidias; Lecia Sequist; Thomas J Lynch; John C Wain; Frances A Shepherd; David C Christiani; Geoffrey Liu
A rapid outcomes ascertainment system improves the quality of prognostic and pharmacogenetic outcomes from observational studies.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2008;17(1):204-11.
2008: Lecia V Sequist; Thomas J Lynch
EGFR tyrosine kinase inhibitors in lung cancer: an evolving story.
Annual review of medicine 2008;59():429-42.
2007: Richard T Penson; Fei Gu; Susan Harris; Mary Martha Thiel; Nat Lawton; Arlan F Fuller; Thomas J Lynch
Hope.
The oncologist 2007;12(9):1105-13.
2007: Thomas J Lynch; Philip D Bonomi; Charles Butts; Angela M Davies; Jeffrey A Engelman; Ramaswamy Govindan; Roy S Herbst; John V Heymach; Bruce E Johnson; Renato G Martins; Roman Perez-Soler; Gregory J Riely; Alan B Sandler; Lecia V Sequist; Mark A Socinski; Kwok-Kin Wong; Carol S Hart
Novel agents in the treatment of lung cancer: Fourth Cambridge Conference.
Clinical cancer research : an official journal of the American Association for Cancer Research 2007;13(15 Pt 2):s4583-8.
2007: Jennifer S Temel; Vicki A Jackson; J Andrew Billings; Constance Dahlin; Susan D Block; Mary K Buss; Patricia Ostler; Panos Fidias; Alona Muzikansky; Joseph A Greer; William F Pirl; Thomas J Lynch
Phase II study: integrated palliative care in newly diagnosed advanced non-small-cell lung cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(17):2377-82.
2007: C. Rebecca Suk Heist; Wei Zhou; Lucian R Chirieac; Thea Cogan-Drew; Geoffrey Liu; Li Su; Donna Neuberg; Thomas J Lynch; John C Wain; David C Christiani
MDM2 polymorphism, survival, and histology in early-stage non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(16):2243-7.
2007: Geoffrey Liu; Wei Zhou; Beow Y Yeap; Li Su; John C Wain; John M Poneros; Norman S Nishioka; Thomas J Lynch; David C Christiani
XRCC1 and XPD polymorphisms and esophageal adenocarcinoma risk.
Carcinogenesis 2007;28(6):1254-8.
2007: Thomas J Lynch; Ed S Kim; Beth Eaby; Jody Garey; Dennis P West; Mario Lacouture
Epidermal growth factor receptor inhibitor-associated cutaneous toxicities: an evolving paradigm in clinical management.
The oncologist 2007;12(5):610-21.
2007: Leena Gandhi; Matthew W Harding; Marcus Neubauer; Corey J Langer; Melvin Moore; Helen J Ross; Bruce E Johnson; Thomas J Lynch
A phase II study of the safety and efficacy of the multidrug resistance inhibitor VX-710 combined with doxorubicin and vincristine in patients with recurrent small cell lung cancer.
Cancer 2007;109(5):924-32.
2007: David M Jackman; Beow Y Yeap; Neal Lindeman; Panos Fidias; Michael S Rabin; Jennifer S Temel; Arthur T Skarin; Matthew Meyerson; Alison J Holmes; Ana M Borras; Boris Freidlin; Patricia Ostler; Joan Lucca; Thomas J Lynch; Bruce E Johnson; Pasi A Janne
Phase II clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for advanced non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(7):760-6.
2007: Andrew J Yee; Thomas J Lynch
CT screening for lung cancer.
The New England journal of medicine 2007;356(7):744-5; author reply 746-7.
2007: Lecia V Sequist; Daphne W Bell; Thomas J Lynch; Daniel A Haber
Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):587-95.
2007: Wei Zhou; C. Rebecca Suk Heist; Geoffrey Liu; Kofi Asomaning; Donna Neuberg; Bruce W Hollis; John C Wain; Thomas J Lynch; Edward Giovannucci; Li Su; David C Christiani
Circulating 25-hydroxyvitamin D levels predict survival in early-stage non-small-cell lung cancer patients.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2007;25(5):479-85.
2007: Lecia V Sequist; Victoria A Joshi; Pasi A Janne; Alona Muzikansky; Panos Fidias; Matthew Meyerson; Daniel A Haber; Raju Kucherlapati; Bruce E Johnson; Thomas J Lynch
Response to treatment and survival of patients with non-small cell lung cancer undergoing somatic EGFR mutation testing.
The oncologist 2007;12(1):90-8.
2006: Wei Zhou; C. Rebecca Suk Heist; Geoffrey Liu; Kofi Asomaning; David P Miller; Donna Neuberg; John C Wain; Thomas J Lynch; David C Christiani
Second hand smoke exposure and survival in early-stage non-small-cell lung cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(23):7187-93.
2006: Nasser Hanna; Rogerio Lilenbaum; Rafat Ansari; Thomas J Lynch; Ramaswamy Govindan; Pasi A Janne; Philip Bonomi
Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(33):5253-8.
2006: David P Ryan; Leonard J Appleman; Thomas J Lynch; Jeffrey G Supko; Panos Fidias; jeffrey clark; Mayer Fishman; Andrew X Zhu; Peter C Enzinger; Oscar Kashala; James C Cusack; Joseph P Eder
Phase I clinical trial of bortezomib in combination with gemcitabine in patients with advanced solid tumors.
Cancer 2006;107(10):2482-9.
2006: Wei Zhou; C. Rebecca Suk Heist; Geoffrey Liu; Donna Neuberg; Kofi Asomaning; Li Su; John C Wain; Thomas J Lynch; Edward Giovannucci; David C Christiani
Polymorphisms of vitamin D receptor and survival in early-stage non-small cell lung cancer patients.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2006;15(11):2239-45.
2006: David P Miller; Kofi Asomaning; Geoffrey Liu; John C Wain; Thomas J Lynch; Donna Neuberg; Li Su; David C Christiani
An association between glutathione S-transferase P1 gene polymorphism and younger age at onset of lung carcinoma.
Cancer 2006;107(7):1570-7.
2006: C. Rebecca Suk Heist; Ariela L Marshall; Geoffrey Liu; Wei Zhou; Li Su; Donna Neuberg; Thomas J Lynch; John Wain; David C Christiani
Matrix metalloproteinase polymorphisms and survival in stage I non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(18):5448-53.
2006: Wei Zhou; C. Rebecca Suk Heist; Geoffrey Liu; Sohee Park; Donna Neuberg; Kofi Asomaning; John C Wain; Thomas J Lynch; David C Christiani
Smoking cessation before diagnosis and survival in early stage non-small cell lung cancer patients.
Lung cancer (Amsterdam, Netherlands) 2006;53(3):375-80.
2006: Matthew H Kulke; Emily K Bergsland; David P Ryan; Peter C Enzinger; Thomas J Lynch; Andrew X Zhu; Jeffrey A Meyerhardt; John V Heymach; William E Fogler; Carolyn Sidor; Ann Michelini; Kate Kinsella; Alan P Venook; Charlie S Fuchs
Phase II study of recombinant human endostatin in patients with advanced neuroendocrine tumors.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2006;24(22):3555-61.
2006: Lecia V Sequist; Victoria A Joshi; Pasi A Janne; Daphne W Bell; Panos Fidias; Neal Lindeman; David N Louis; Jeffrey C Lee; Eugene J Mark; Janina Longtine; Peter Verlander; Raju Kucherlapati; Matthew Meyerson; Daniel A Haber; Bruce E Johnson; Thomas J Lynch
Epidermal growth factor receptor mutation testing in the care of lung cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 2):4403s-4408s.
2006: Thomas J Lynch; Alex A. Adjei; Paul A Bunn; Tim G Eisen; Jeffrey A Engelman; Glenwood Goss; Daniel A Haber; John V Heymach; Pasi A Janne; Bruce E Johnson; David H Johnson; Rogerio Lilenbaum; Matthew Meyerson; Alan B Sandler; Lecia V Sequist; Jeffrey Settleman; Kwok-Kin Wong; Carol S Hart
Summary statement: novel agents in the treatment of lung cancer: advances in epidermal growth factor receptor-targeted agents.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(14 Pt 2):4365s-4371s.
2006: Kevin S Roof; John J Coen; Thomas J Lynch; Cameron Wright; Panos Fidias; Christopher G Willett; Noah C Choi
Concurrent cisplatin, 5-FU, paclitaxel, and radiation therapy in patients with locally advanced esophageal cancer.
International journal of radiation oncology, biology, physics 2006;65(4):1120-8.
2006: David M Jackman; Beow Y Yeap; Lecia V Sequist; Neal Lindeman; Alison J Holmes; Victoria A Joshi; Daphne W Bell; Mark S Huberman; Balazs Halmos; Michael S Rabin; Daniel A Haber; Thomas J Lynch; Matthew Meyerson; Bruce E Johnson; Pasi A Janne
Exon 19 deletion mutations of epidermal growth factor receptor are associated with prolonged survival in non-small cell lung cancer patients treated with gefitinib or erlotinib.
Clinical cancer research : an official journal of the American Association for Cancer Research 2006;12(13):3908-14.
2006: Jennifer S Temel; William F Pirl; Christopher J Recklitis; Barbara Cashavelly; Thomas J Lynch
Feasibility and validity of a one-item fatigue screen in a thoracic oncology clinic.
Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer 2006;1(5):454-9.
2006: Richard T Penson; Helena Kyriakou; Dan Zuckerman; Bruce A Chabner; Thomas J Lynch
Teams: communication in multidisciplinary care.
The oncologist 2006;11(5):520-6.
2006: Li Su; Wei Zhou; Kofi Asomaning; Xihong Lin; John C Wain; Thomas J Lynch; Geoffrey Liu; David C Christiani
Genotypes and haplotypes of matrix metalloproteinase 1, 3 and 12 genes and the risk of lung cancer.
Carcinogenesis 2006;27(5):1024-9.
2006: Matthew H Kulke; Bingyan Wu; jeffrey clark; Peter C Enzinger; Thomas J Lynch; Michele Vincitore; Ann Michelini; Charlie S Fuchs
A phase II study of doxorubicin, cisplatin, and 5-fluorouracil in patients with advanced adenocarcinoma of the stomach or esophagus.
Cancer investigation 2006;24(3):229-34.
2006: Gregory A Abel; Richard T Penson; Steven Joffe; Lidia Schapira; Bruce A Chabner; Thomas J Lynch
Direct-to-consumer advertising in oncology.
The oncologist 2006;11(2):217-26.
2006: Jennifer S Temel; William F Pirl; Thomas J Lynch
Comprehensive symptom management in patients with advanced-stage non-small-cell lung cancer.
Clinical lung cancer 2006;7(4):241-9.
2005: Wei Zhou; Sohee Park; Geoffrey Liu; David P Miller; Lisa I Wang; Lucille Pothier; John C Wain; Thomas J Lynch; Edward Giovannucci; David C Christiani
Dietary iron, zinc, and calcium and the risk of lung cancer.
Epidemiology (Cambridge, Mass.) 2005;16(6):772-9.
2005: Daphne W Bell; Thomas J Lynch; Sara M Haserlat; Patricia Neal; Ross A Okimoto; Brian W Brannigan; Dennis C Sgroi; Beth Muir; Markus J Riemenschneider; Renee Bailey Iacona; Annetta D Krebs; David H Johnson; Giuseppe Giaccone; Roy S Herbst; Christian Manegold; Masahiro Fukuoka; Mark G Kris; José Baselga; Judith S Ochs; Daniel A Haber
Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(31):8081-92.
2005: Wei Zhou; Rebecca Suk; Geoffrey Liu; Sohee Park; Donna Neuberg; John C Wain; Thomas J Lynch; Edward Giovannucci; David C Christiani
Vitamin D is associated with improved survival in early-stage non-small cell lung cancer patients.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(10):2303-9.
2005: Thomas J Lynch
Predictive tests for EGFR inhibitors.
Clinical advances in hematology & oncology : H&O 2005;3(9):678-9.
2005: Richard T Penson; Rosamund A Partridge; Pandora Rudd; Michael Seiden; Jill E Nelson; Bruce A Chabner; Thomas J Lynch
Laughter: the best medicine?
The oncologist 2005;10(8):651-60.
2005: Lecia V Sequist; Daniel A Haber; Thomas J Lynch
Epidermal growth factor receptor mutations in non-small cell lung cancer: predicting clinical response to kinase inhibitors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(16):5668-70.
2005: Thomas J Lynch; Jeffrey A. Bogart; Walter Curran; Malcolm M DeCamp; David R Gandara; Glenwood Goss; Claudia I Henschke; James R Jett; Bruce E Johnson; Karen L Kelly; Thierry Le Chevalier; James L Mulshine; Giorgio V Scagliotti; Joan H Schiller; Alice Shaw; Nick Thatcher; Everett E Vokes; Douglas E Wood; Carol Hart
Early stage lung cancer--new approaches to evaluation and treatment: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(13 Pt 2):4981s-4983s.
2005: Sarada Gurubhagavatula; Thomas J Lynch
The role of adjuvant chemotherapy for non-small cell lung cancer.
Seminars in respiratory and critical care medicine 2005;26(3):298-303.
2005: Brian M Wolpin; Bruce A Chabner; Thomas J Lynch; Richard T Penson
Learning to cope: how far is too close?
The oncologist 2005;10(6):449-56.
2005: Eunice L Kwak; Raffaella Sordella; Daphne W Bell; Nadia Godin-Heymann; Ross A Okimoto; Brian W Brannigan; Patricia Neal; David R Driscoll; Panos Fidias; Thomas J Lynch; Sridhar K Rabindran; John P McGinnis; Allan Wissner; Sreenath V Sharma; Kurt J Isselbacher; Jeffrey Settleman; Daniel A Haber
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib.
Proceedings of the National Academy of Sciences of the United States of America 2005;102(21):7665-70.
2005: John R Goffin; Ian C Anderson; Jeffrey G Supko; Joseph P Eder; Geoffrey I Shapiro; Thomas J Lynch; Margaret A Shipp; Bruce E Johnson; Arthur T Skarin
Phase I trial of the matrix metalloproteinase inhibitor marimastat combined with carboplatin and paclitaxel in patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(9):3417-24.
2005: Johanna C Bendell; Joseph P Eder; jeffrey clark; Panos Fidias; Thomas J Lynch; Michael Seiden; David P Ryan
Phase I dose-escalation study of tezacitabine in combination with 5-fluorouracil in patients with advanced solid tumors.
Cancer 2005;103(9):1925-31.
2005: David Cella; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Anne Heyes; Judith S Ochs; Michael K Wolf; Andrea C Kay; Mark G Kris; Ronald B Natale
Clinically meaningful improvement in symptoms and quality of life for patients with non-small-cell lung cancer receiving gefitinib in a randomized controlled trial.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2005;23(13):2946-54.
2005: Li Su; Wei Zhou; Sohee Park; John C Wain; Thomas J Lynch; Geoffrey Liu; David C Christiani
Matrix metalloproteinase-1 promoter polymorphism and lung cancer risk.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(3):567-70.
2005: Rebecca Suk; Sarada Gurubhagavatula; Sohee Park; Wei Zhou; Li Su; Thomas J Lynch; John C Wain; Donna Neuberg; Geoffrey Liu; David C Christiani
Polymorphisms in ERCC1 and grade 3 or 4 toxicity in non-small cell lung cancer patients.
Clinical cancer research : an official journal of the American Association for Cancer Research 2005;11(4):1534-8.
2005: Wei Zhou; Geoffrey Liu; Sohee Park; Zhaoxi Wang; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Gene-smoking interaction associations for the ERCC1 polymorphisms in the risk of lung cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2005;14(2):491-6.
2005: Richard T Penson; Rosamund A Partridge; Muhammad A Shah; David Giansiracusa; Bruce A Chabner; Thomas J Lynch
Fear of death.
The oncologist 2005;10(2):160-9.
2005: Daniel A Haber; Daphne W Bell; Raffaella Sordella; Eunice L Kwak; Nadia Godin-Heymann; Sreenath V Sharma; Thomas J Lynch; Jeffrey Settleman
Molecular targeted therapy of lung cancer: EGFR mutations and response to EGFR inhibitors.
Cold Spring Harbor symposia on quantitative biology 2005;70():419-26.
2005: Tracey L Evans; Thomas J Lynch
Role of chemotherapy in the management of advanced thymic tumors.
Seminars in thoracic and cardiovascular surgery 2005;17(1):41-50.
2004: Geoffrey Liu; Wei Zhou; Sohee Park; Lisa I Wang; David P Miller; John C Wain; Thomas J Lynch; Li Su; David C Christiani
The SOD2 Val/Val genotype enhances the risk of nonsmall cell lung carcinoma by p53 and XRCC1 polymorphisms.
Cancer 2004;101(12):2802-8.
2004: Thomas J Lynch
The evolving story of the epidermal growth factor receptor as a target for non-small-cell lung cancer.
Clinical advances in hematology & oncology : H&O 2004;2(12):786-7.
2004: Geoffrey Liu; Wei Zhou; Lisa I Wang; Sohee Park; David P Miller; Li Lian Xu; John C Wain; Thomas J Lynch; Li Su; David C Christiani
MPO and SOD2 polymorphisms, gender, and the risk of non-small cell lung carcinoma.
Cancer letters 2004;214(1):69-79.
2004: Noah Choi; Sung D Park; Thomas J Lynch; Cameron Wright; Marek Ancukiewicz; John Wain; Dean Donahue; Douglas J Mathisen
Twice-daily radiotherapy as concurrent boost technique during two chemotherapy cycles in neoadjuvant chemoradiotherapy for resectable esophageal carcinoma: mature results of phase II study.
International journal of radiation oncology, biology, physics 2004;60(1):111-22.
2004: Matthew H Kulke; Haesook T Kim; jeffrey clark; Peter C Enzinger; Thomas J Lynch; Jeffrey A Morgan; Michele Vincitore; Ann Michelini; Charlie S Fuchs
A Phase II trial of gemcitabine for metastatic neuroendocrine tumors.
Cancer 2004;101(5):934-9.
2004: Thomas J Lynch; Cameron D Wright; Noah C Choi; Suzanne L Aquino; Eugene J Mark
Case records of the Massachusetts General Hospital. Weekly clinicopathological exercises. Case 26-2004. A 56-year-old woman with cough and a lung nodule.
The New England journal of medicine 2004;351(8):809-17.
2004: Wei Zhou; Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Donna Neuberg; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Excision repair cross-complementation group 1 polymorphism predicts overall survival in advanced non-small cell lung cancer patients treated with platinum-based chemotherapy.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(15):4939-43.
2004: Sarada Gurubhagavatula; Geoffrey Liu; Sohee Park; Wei Zhou; Li Su; John C Wain; Thomas J Lynch; Donna Neuberg; David C Christiani
XPD and XRCC1 genetic polymorphisms are prognostic factors in advanced non-small-cell lung cancer patients treated with platinum chemotherapy.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2004;22(13):2594-601.
2004: Thomas J Lynch; Alex A. Adjei; Paul A Bunn; Raymond DuBois; David R Gandara; Giuseppe Giaccone; Ramaswamy Govindan; Roy S Herbst; Bruce E Johnson; Fadlo R Khuri; Roman Perez-Soler; Rafael Rosell; Eric K Rowinsky; Alan B Sandler; Giorgio V Scagliotti; Joan H Schiller; Geoffrey I Shapiro; Mark A Socinski; Carol S Hart
Novel agents in the treatment of lung cancer: conference summary statement.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(12 Pt 2):4199s-4204s.
2004: Thomas J Lynch; Daphne W Bell; Raffaella Sordella; Sarada Gurubhagavatula; Ross A Okimoto; Brian W Brannigan; Patricia Neal; Sara M Haserlat; Jeffrey G Supko; Frank G Haluska; David N Louis; David C Christiani; Jeffrey Settleman; Daniel A Haber
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib.
The New England journal of medicine 2004;350(21):2129-39.
2004: Pasi A Janne; Sarada Gurubhagavatula; Beow Y Yeap; Joan Lucca; Patricia Ostler; Arthur T Skarin; Panos Fidias; Thomas J Lynch; Bruce E Johnson
Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, "Iressa") on an expanded access study.
Lung cancer (Amsterdam, Netherlands) 2004;44(2):221-30.
2004: David P Ryan; Joseph P Eder; Thomas Puchlaski; Michael Seiden; Thomas J Lynch; Charlie S Fuchs; Philip C Amrein; Daryl S Sonnichsen; Jeffrey G Supko; jeffrey clark
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 given as a 1-hour intravenous infusion in patients with advanced solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2004;10(7):2222-30.
2004: Elizabeth Johnson; Diana Lake; James E Herndon; James W Box; Thomas J Lynch; Mark R Green
Phase II trial of vinorelbine plus doxorubicin in relapsed small-cell lung cancer: CALGB 9332.
American journal of clinical oncology 2004;27(1):19-23.
2004: Richard T Penson; Lidia Schapira; Kristy J Daniels; Bruce A Chabner; Thomas J Lynch
Cancer as metaphor.
The oncologist 2004;9(6):708-16.
2004: Richard T Penson; Kristy J Daniels; Thomas J Lynch
Too old to care?
The oncologist 2004;9(3):343-52.
2004: Richard T Penson; Shivali H G Talsania; Bruce A Chabner; Thomas J Lynch
Help me help you: support groups in cancer therapy.
The oncologist 2004;9(2):217-25.
2003: Jeffrey G Supko; Joseph P Eder; David P Ryan; Michael Seiden; Thomas J Lynch; Philip C Amrein; Donald Kufe; jeffrey clark
Phase I clinical trial and pharmacokinetic study of the spicamycin analog KRN5500 administered as a 1-hour intravenous infusion for five consecutive days to patients with refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2003;9(14):5178-86.
2003: Kevin S Roof; Panos Fidias; Thomas J Lynch; Marek Ancukiewicz; Noah C Choi
Radiation dose escalation in limited-stage small-cell lung cancer.
International journal of radiation oncology, biology, physics 2003;57(3):701-8.
2003: Mark G Kris; Ronald B Natale; Roy S Herbst; Thomas J Lynch; Diane Prager; Chandra P Belani; Joan H Schiller; Karen Kelly; Harris Spiridonidis; Alan B Sandler; Kathy S Albain; David Cella; Michael K Wolf; Steven D Averbuch; Judith J Ochs; Andrea C Kay
Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial.
JAMA : the journal of the American Medical Association 2003;290(16):2149-58.
2003: Thomas G Roberts; Thomas J Lynch; Bruce A Chabner
The phase III trial in the era of targeted therapy: unraveling the "go or no go" decision.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(19):3683-95.
2003: Mikkael A Sekeres; Miriam Chernoff; Thomas J Lynch; Eydie I Kasendorf; Daniel H Lasser; Donna B Greenberg
The impact of a physician awareness group and the first year of training on hematology-oncology fellows.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(19):3676-82.
2003: David P Miller; Donna Neuberg; Immaculata DeVivo; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Smoking and the risk of lung cancer: susceptibility with GSTP1 polymorphisms.
Epidemiology (Cambridge, Mass.) 2003;14(5):545-51.
2003: Lecia V Sequist; Thomas J Lynch
Aggressive treatment for the fit elderly with non-small-cell lung cancer? Yes!
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(17):3186-8.
2003: Li Su; Yang Sai; Rong Fan; Sally W Thurston; David P Miller; Wei Zhou; John C Wain; Thomas J Lynch; Geoffrey Liu; David C Christiani
P53 (codon 72) and P21 (codon 31) polymorphisms alter in vivo mRNA expression of p21.
Lung cancer (Amsterdam, Netherlands) 2003;40(3):259-66.
2003: David P Miller; Immaculata DeVivo; Donna Neuberg; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Association between self-reported environmental tobacco smoke exposure and lung cancer: modification by GSTP1 polymorphism.
International journal of cancer. Journal international du cancer 2003;104(6):758-63.
2003: Kevin S Roof; Panos Fidias; Thomas J Lynch; Noah C Choi
Radiation dose intensification in limited-stage small-cell lung cancer.
Clinical lung cancer 2003;4(6):339-46.
2003: Wei Zhou; Geoffrey Liu; David P Miller; Sally W Thurston; Li Lian Xu; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Polymorphisms in the DNA repair genes XRCC1 and ERCC2, smoking, and lung cancer risk.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2003;12(4):359-65.
2003: Ravi Salgia; Thomas J Lynch; Arthur T Skarin; Joan Lucca; Cathy Lynch; Ken Jung; F Stephen Hodi; Michael T Jaklitsch; Steven J Mentzer; Scott Swanson; Jeanne M Lukanich; Raphael Bueno; John Wain; Douglas J Mathisen; Cameron Wright; Panos Fidias; Dean Donahue; Shirley Clift; Steve Hardy; Donna Neuberg; Richard Mulligan; Iain Webb; David J Sugarbaker; Martin Mihm; Glenn Dranoff
Vaccination with irradiated autologous tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor augments antitumor immunity in some patients with metastatic non-small-cell lung carcinoma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2003;21(4):624-30.
2003: Li Su; Geoffrey Liu; Wei Zhou; Li Lian Xu; David P Miller; Sohee Park; Thomas J Lynch; John C Wain; David C Christiani
No association between the p21 codon 31 serine-arginine polymorphism and lung cancer risk.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2003;12(2):174-5.
2003: Lauren Dias; Bruce A Chabner; Thomas J Lynch; Richard T Penson
Breaking bad news: a patient's perspective.
The oncologist 2003;8(6):587-96.
2003: Richard T Penson; Laura A Fergus; Ross J Haston; John R Clark; Andrew Demotses; James J O'Connell; Bruce A Chabner; Thomas J Lynch
The Kenneth B. Schwartz Center at Massachusetts General Hospital hematology-oncology department: hope for the homeless.
The oncologist 2003;8(5):488-95.
2003: Richard T Penson; Catherine Nunn; Jerry Younger; Nancy J Schaeffer; Bruce A Chabner; Gregory L Fricchione; Thomas E Quinn; Thomas J Lynch
Trust violated: analgesics for addicts.
The oncologist 2003;8(2):199-209.
2003: Kristine A Knuti; Robert H Wharton; Karen Levine Wharton; Bruce A Chabner; Thomas J Lynch; Richard T Penson
Living as a cancer surpriser: a doctor tells his story.
The oncologist 2003;8(1):108-22.
2002: Li Lian Xu; Geoffrey Liu; David P Miller; Wei Zhou; Thomas J Lynch; John C Wain; Li Su; David C Christiani
Counterpoint: the myeloperoxidase -463G-->a polymorphism does not decrease lung cancer susceptibility in Caucasians.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002;11(12):1555-9.
2002: Frank V Fossella; Thomas J Lynch; Frances A Shepherd
Second line chemotherapy for NSCLC: establishing a gold standard.
Lung cancer (Amsterdam, Netherlands) 2002;38 Suppl 4():5-12.
2002: Noah C Choi; Alan J Fischman; Andrzej Niemierko; Jin Sook Ryu; Thomas J Lynch; John Wain; Cameron Wright; Panos Fidias; Douglas J Mathisen
Dose-response relationship between probability of pathologic tumor control and glucose metabolic rate measured with FDG PET after preoperative chemoradiotherapy in locally advanced non-small-cell lung cancer.
International journal of radiation oncology, biology, physics 2002;54(4):1024-35.
2002: David P Miller; Geoffrey Liu; Immaculata DeVivo; Thomas J Lynch; John C Wain; Li Su; David C Christiani
Combinations of the variant genotypes of GSTP1, GSTM1, and p53 are associated with an increased lung cancer risk.
Cancer research 2002;62(10):2819-23.
2002: F Stephen Hodi; Jan C Schmollinger; Robert J Soiffer; Ravi Salgia; Thomas J Lynch; Jerome Ritz; Edwin P Alyea; Jihong Yang; Donna Neuberg; Martin Mihm; Glenn Dranoff
ATP6S1 elicits potent humoral responses associated with immune-mediated tumor destruction.
Proceedings of the National Academy of Sciences of the United States of America 2002;99(10):6919-24.
2002: Cameron D Wright; Matthew T Menard; John C Wain; Dean M Donahue; Hermes C Grillo; Thomas J Lynch; Noah C Choi; Douglas J Mathisen
Induction chemoradiation compared with induction radiation for lung cancer involving the superior sulcus.
The Annals of thoracic surgery 2002;73(5):1541-4.
2002: Tracey L Evans; Dean M Donahue; Douglas J Mathisen; Thomas J Lynch
Building a better therapy for stage IIIA non-small cell lung cancer.
Clinics in chest medicine 2002;23(1):191-207.
2002: Michael Seiden; Shu-Wing Ng; Jeffrey G Supko; David P Ryan; jeffrey clark; Thomas J Lynch; Kuan-Chun Huang; David Kwiatkowski; Arthur T Skarin; Joseph P Eder
A phase I clinical trial of sequentially administered doxorubicin and topotecan in refractory solid tumors.
Clinical cancer research : an official journal of the American Association for Cancer Research 2002;8(3):691-7.
2002: Wei Zhou; Geoffrey Liu; David P Miller; Sally W Thurston; Li Lian Xu; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Gene-environment interaction for the ERCC2 polymorphisms and cumulative cigarette smoking exposure in lung cancer.
Cancer research 2002;62(5):1377-81.
2002: Panos Fidias; Michael L Grossbard; Thomas J Lynch
A phase II study of the immunotoxin N901-blocked ricin in small-cell lung cancer.
Clinical lung cancer 2002;3(3):219-22.
2002: Alan P Lyss; James E Herndon; Thomas J Lynch; Andrew T Turrisi; Dorothy M Watson; Sara J Grethlein; Mark R Green
Novel doublets in extensive-stage small-cell lung cancer: a randomized phase II study of topotecan plus cisplatin or paclitaxel (CALGB 9430).
Clinical lung cancer 2002;3(3):205-10; discussion 211-2.
2002: Jin Sook Ryu; Noah C Choi; Alan J Fischman; Thomas J Lynch; Douglas J Mathisen
FDG-PET in staging and restaging non-small cell lung cancer after neoadjuvant chemoradiotherapy: correlation with histopathology.
Lung cancer (Amsterdam, Netherlands) 2002;35(2):179-87.
2002: Richard T Penson; Renee C Benson; Karen Parles; Bruce A Chabner; Thomas J Lynch
Virtual connections: Internet health care.
The oncologist 2002;7(6):555-68.
2002: Kristine A Knuti; Philip C Amrein; Bruce A Chabner; Thomas J Lynch; Richard T Penson
Faith, identity, and leukemia: when blood products are not an option.
The oncologist 2002;7(4):371-80.
2002: Richard T Penson; Kara M Green; Bruce A Chabner; Thomas J Lynch
When does the responsibility of our care end: bereavement.
The oncologist 2002;7(3):251-8.
2002: Thomas G Roberts; Thomas J Lynch; Bruce A Chabner
Choosing chemotherapy for lung cancer based on cost: not yet.
The oncologist 2002;7(3):177-8.
2002: Richard T Penson; Paula K Rauch; Steve L McAfee; Barbara J Cashavelly; Kathy Clair-Hayes; Constance Dahlin; Kara M Green; Bruce A Chabner; Thomas J Lynch
Between parent and child: negotiating cancer treatment in adolescents.
The oncologist 2002;7(2):154-62.
2002: Wei Zhou; Geoffrey Liu; Sally W Thurston; Li Lian Xu; David P Miller; John C Wain; Thomas J Lynch; Li Su; David C Christiani
Genetic polymorphisms in N-acetyltransferase-2 and microsomal epoxide hydrolase, cumulative cigarette smoking, and lung cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2002;11(1):15-21.
2001: Geoffrey Liu; David P Miller; Wei Zhou; Sally W Thurston; R Fan; Li Lian Xu; Thomas J Lynch; John C Wain; Li Su; David C Christiani
Differential association of the codon 72 p53 and GSTM1 polymorphisms on histological subtype of non-small cell lung carcinoma.
Cancer research 2001;61(24):8718-22.
2001: Lisa I Wang; David P Miller; Y Sai; Geoffrey Liu; Li Su; John C Wain; Thomas J Lynch; David C Christiani
Manganese superoxide dismutase alanine-to-valine polymorphism at codon 16 and lung cancer risk.
Journal of the National Cancer Institute 2001;93(23):1818-21.
2001: Panos Fidias; Jeffrey G Supko; R Martins; A Boral; R Carey; M Grossbard; G Shapiro; Patricia Ostler; Joan Lucca; Bruce E Johnson; Arthur T Skarin; Thomas J Lynch
A phase II study of weekly paclitaxel in elderly patients with advanced non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(12):3942-9.
2001: Craig A Bunnell; Jeffrey G Supko; Joseph P Eder; jeffrey clark; Thomas J Lynch; Donald Kufe; Larry N Shulman
Phase I clinical trial of 7-cyanoquinocarcinol (DX-52-1) in adult patients with refractory solid malignancies.
Cancer chemotherapy and pharmacology 2001;48(5):347-55.
2001: B H Goulart; R G Martins; Thomas J Lynch
Twenty-two years of phase III trials for patients with advanced non-small-cell lung cancer: sobering results.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2001;19(20):4089.
2001: Thomas J Lynch
Review of two phase III randomized trials of single-agent docetaxel in previously treated advanced non--small cell lung cancer.
Seminars in oncology 2001;28(3 Suppl 9):5-9.
2001: Geoffrey I Shapiro; Jeffrey G Supko; A Patterson; Cathy Lynch; Joan Lucca; P F Zacarola; Alona Muzikansky; J J Wright; Thomas J Lynch; Barrett J Rollins
A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(6):1590-9.
2001: Wei Zhou; Sally W Thurston; Geoffrey Liu; Li Lian Xu; David P Miller; John C Wain; Thomas J Lynch; Li Su; David C Christiani
The interaction between microsomal epoxide hydrolase polymorphisms and cumulative cigarette smoking in different histological subtypes of lung cancer.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(5):461-6.
2001: Li Lian Xu; John C Wain; David P Miller; Sally W Thurston; Li Su; Thomas J Lynch; David C Christiani
The NAD(P)H:quinone oxidoreductase 1 gene polymorphism and lung cancer: differential susceptibility based on smoking behavior.
Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology 2001;10(4):303-9.
2001: Frances A Shepherd; F V Fossella; Thomas J Lynch; J P Armand; James R Rigas; Mark G Kris
Docetaxel (Taxotere) shows survival and quality-of-life benefits in the second-line treatment of non-small cell lung cancer: a review of two phase III trials.
Seminars in oncology 2001;28(1 Suppl 2):4-9.
2001: Chandra P Belani; Thomas J Lynch
Docetaxel (Taxotere) in combination with platinums in patients with non-small cell lung cancer: trial data and implications for clinical management.
Seminars in oncology 2001;28(1 Suppl 2):10-4.
2001: David P Ryan; Jeffrey G Supko; Joseph P Eder; Michael Seiden; George D Demetri; Thomas J Lynch; A J Fischman; J Davis; J Jimeno; jeffrey clark
Phase I and pharmacokinetic study of ecteinascidin 743 administered as a 72-hour continuous intravenous infusion in patients with solid malignancies.
Clinical cancer research : an official journal of the American Association for Cancer Research 2001;7(2):231-42.
2001: Richard T Penson; C M Castro; Michael Seiden; Bruce A Chabner; Thomas J Lynch
Complementary, alternative, integrative, or unconventional medicine?
The oncologist 2001;6(5):463-73.
2001: T L Evans; Thomas J Lynch
Lung cancer.
The oncologist 2001;6(5):407-14.
2001: Richard T Penson; Rushdia Z Yusuf; Bruce A Chabner; J P Lafrancesca; M McElhinny; A S Axelrad; Thomas J Lynch
Losing God.
The oncologist 2001;6(3):286-97.
2001: Richard T Penson; Michael Seiden; Bruce A Chabner; Thomas J Lynch
Caring for colleagues.
The oncologist 2001;6(2):197-204.
2001: R T Penson; S S Svendsen; B A Chabner; Thomas J Lynch; W Levinson
Medical mistakes: a workshop on personal perspectives.
The oncologist 2001;6(1):92-9.
2000: M Myojin; Noah C Choi; Cameron D Wright; John C Wain; N Harris; Eugen B Hug; Douglas J Mathisen; Thomas J Lynch; RW Carey; Michael L Grossbard; DM Finkelstein; Hermes C Grillo
Stage III thymoma: pattern of failure after surgery and postoperative radiotherapy and its implication for future study.
International journal of radiation oncology, biology, physics 2000;46(4):927-33.
2000: Jeffrey G Supko; Thomas J Lynch; jeffrey clark; Robert J Fram; L F Allen; R Velagapudi; Donald Kufe; Joseph P Eder
A phase I clinical and pharmacokinetic study of the dolastatin analogue cemadotin administered as a 5-day continuous intravenous infusion.
Cancer chemotherapy and pharmacology 2000;46(4):319-28.
2000: Richard T Penson; F L Dignan; George P Canellos; C L Picard; Thomas J Lynch
Burnout: caring for the caregivers.
The oncologist 2000;5(5):425-34.
2000: Richard T Penson; J Gallagher; M E Gioiella; M Wallace; K Borden; L A Duska; J A Talcott; F J McGovern; Leonard J Appleman; Bruce A Chabner; Thomas J Lynch
Sexuality and cancer: conversation comfort zone.
The oncologist 2000;5(4):336-44.
2000: Thomas J Lynch
Lung cancer highlights.
The oncologist 2000;5(4):274-9.
2000: RT Penson; Michael Seiden; K M Shannon; M L Lubratovich; M Roche; Bruce A Chabner; Thomas J Lynch
Communicating genetic risk: pros, cons, and counsel.
The oncologist 2000;5(2):152-61.
2000: E L Krakauer; RT Penson; R D Truog; L A King; Bruce A Chabner; Thomas J Lynch
Sedation for intractable distress of a dying patient: acute palliative care and the principle of double effect.
The oncologist 2000;5(1):53-62.
2000: D P Ryan; Thomas J Lynch; M L Grossbard; Michael Seiden; Charlie S Fuchs; N Grenon; P Baccala; D Berg; D Finkelstein; Robert J Mayer; jeffrey clark
A phase I study of gemcitabine and docetaxel in patients with metastatic solid tumors.
Cancer 2000;88(1):180-5.
1999: D P Ryan; RT Penson; S Ahmed; Bruce A Chabner; Thomas J Lynch
Reality testing in cancer treatment: the phase I trial of endostatin.
The oncologist 1999;4(6):501-8.
1999: A Goodman; R T Penson; R Blatman; J McIntyre; M E Gioiella; Bruce A Chabner; Thomas J Lynch
A staff dialogue on a socially distanced patient: psychosocial issues faced by patients, their families, and caregivers.
The oncologist 1999;4(5):417-24.
1999: Thomas J Lynch
Lung cancer highlights.
The oncologist 1999;4(4):279-86.
1999: E M O'Shea; RT Penson; T A Stern; J Younger; Bruce A Chabner; Thomas J Lynch
A staff dialogue on do not resuscitate orders: psychosocial issues faced by patients, their families, and caregivers.
The oncologist 1999;4(3):256-62.
1999: E M O'Shea; K C Lintz; RT Penson; Michael Seiden; Bruce A Chabner; Thomas J Lynch
A staff dialogue on caring for a cancer patient who commits suicide: psychosocial issues faced by patients, their families, and caregivers.
The oncologist 1999;4(2):122-7.
1999: K C Lintz; RT Penson; N Cassem; D C Harmon; Bruce A Chabner; Thomas J Lynch
A staff dialogue on aggressive palliative treatment demanded by a terminally ill patient: psychosocial issues faced by patients, their families, and caregivers.
The oncologist 1999;4(1):70-6.
1998: Robert J Soiffer; Thomas J Lynch; Martin Mihm; Ken Jung; C Rhuda; Jan C Schmollinger; F Stephen Hodi; L Liebster; P Lam; Steven J Mentzer; Samuel Singer; Kenneth Tanabe; A B Cosimi; Rosemary B Duda; A Sober; A Bhan; J Daley; Donna Neuberg; G Parry; Joseph Rokovich; L Richards; J Drayer; A Berns; Shirley Clift; LK Cohen; Richard C Mulligan; Glenn Dranoff
Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patients with metastatic melanoma.
Proceedings of the National Academy of Sciences of the United States of America 1998;95(22):13141-6.
1998: Joseph P Eder; Jeffrey G Supko; Thomas J Lynch; M Bryant; Evan Vosburgh; Larry N Shulman; G Xu; Donald Kufe
Phase I trial of the colloidal dispersion formulation of 9-amino-20(S)-camptothecin administered as a 72-hour continuous intravenous infusion.
Clinical cancer research : an official journal of the American Association for Cancer Research 1998;4(2):317-24.
1998: J E O'Toole; Dixie Esseltine; Thomas J Lynch; JM Lambert; Michael L Grossbard
Clinical trials with blocked ricin immunotoxins.
Current topics in microbiology and immunology 1998;234():35-56.
1997: Cameron D Wright; John C Wain; Thomas J Lynch; Noah C Choi; M L Grossbard; RW Carey; Ashby C Moncure; Hermes C Grillo; Douglas J Mathisen
Induction therapy for esophageal cancer with paclitaxel and hyperfractionated radiotherapy: a phase I and II study.
The Journal of thoracic and cardiovascular surgery 1997;114(5):811-5; discussion 816.
1997: Gary M Strauss; Thomas J Lynch; Anthony D Elias; C Jacobs; R Herbst; T Leong; C Lynch; D J Kwiatkowski; RW Carey; Michael L Grossbard; Arthur T Skarin
Ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer: update and preliminary survival analysis.
Seminars in oncology 1997;24(4 Suppl 12):S12-73-S12-80.
1997: Anthony D Elias; Arthur T Skarin; T Leong; S Mentzer; G Strauss; Thomas J Lynch; L Shulman; C Jacobs; A Abner; Elizabeth Baldini; E Frei; David J Sugarbaker
Neoadjuvant therapy for surgically staged IIIA N2 non-small cell lung cancer (NSCLC).
Lung cancer (Amsterdam, Netherlands) 1997;17(1):147-61.
1997: Thomas J Lynch; JM Lambert; F Coral; J Shefner; Patrick Y Wen; W A Blattler; A R Collinson; P D Ariniello; G Braman; S Cook; Dixie Esseltine; A Elias; Arthur T Skarin; Jerome Ritz
Immunotoxin therapy of small-cell lung cancer: a phase I study of N901-blocked ricin.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):723-34.
1997: Noah C Choi; RW Carey; WJ Daly; Douglas J Mathisen; John Wain; Cameron Wright; Thomas J Lynch; Michael L Grossbard; Hermes C Grillo
Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemotherapy in stage IIIA non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1997;15(2):712-22.
1997: Glenn Dranoff; Robert J Soiffer; Thomas J Lynch; Martin Mihm; Ken Jung; K Kolesar; L Liebster; P Lam; Rosemary B Duda; Steven J Mentzer; Samuel Singer; Kenneth Tanabe; R Johnson; Arthur J Sober; A Bhan; Shirley Clift; L Cohen; G Parry; Joseph Rokovich; L Richards; J Drayer; A Berns; Richard C Mulligan
A phase I study of vaccination with autologous, irradiated melanoma cells engineered to secrete human granulocyte-macrophage colony stimulating factor.
Human gene therapy 1997;8(1):111-23.
1996: Joseph P Eder; E Rubin; Richard M Stone; M Bryant; G Xu; J Supko; N Kinchla; Thomas J Lynch; S Hurwitz; D Rodriguez; C Shapiro; D Toppmeyer; Michael L Grossbard; E Vosburg; M Huberman; Lowell E Schnipper; Larry N Shulman; Donald Kufe
Trials of 9-amino-20(S)-camptothecin in Boston.
Annals of the New York Academy of Sciences 1996;803():247-55.
1996: Thomas J Lynch; M J Weinstein; D L Tankersley; J C Fratantoni; J S Finlayson
Considerations of pool size in the manufacture of plasma derivatives.
Transfusion 1996;36(9):770-5.
1996: Antonius A Miller; R C Lilenbaum; Thomas J Lynch; Gary Rosner; M J Ratain; M R Green; Richard L Schilsky
Treatment-related fatal sepsis from topotecan/cisplatin and topotecan/paclitaxel.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1996;14(6):1964-5.
1996: Douglas J Mathisen; J C Wain; C Wright; N Choi; R Carey; Alan D Hilgenberg; Michael L Grossbard; Thomas J Lynch; H Grillo
Assessment of preoperative accelerated radiotherapy and chemotherapy in stage IIIA (N2) non-small-cell lung cancer.
The Journal of thoracic and cardiovascular surgery 1996;111(1):123-31; discussion 131-3.
1995: Gary M Strauss; Thomas J Lynch; Anthony D Elias; C Jacobs; David J Kwiatkowski; Larry N Shulman; RW Carey; Michael L Grossbard; S Jauss; David J Sugarbaker
A phase I study of ifosfamide/carboplatin/etoposide/paclitaxel in advanced lung cancer.
Seminars in oncology 1995;22(4 Suppl 9):70-4.
1995: Gary M Strauss; David J Kwiatkowski; David H Harpole; Thomas J Lynch; Arthur T Skarin; David J Sugarbaker
Molecular and pathologic markers in stage I non-small-cell carcinoma of the lung.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1995;13(5):1265-79.
1994: Thomas J Lynch; L A Kalish; F Kass; G Strauss; A Elias; Arthur T Skarin; Larry N Shulman; David J Sugarbaker; Emil Frei
Continuous-infusion cisplatin, 5-fluorouracil, and leucovorin for advanced non-small cell lung cancer.
Cancer 1994;73(4):1171-6.
1994: Thomas J Lynch; L Kalish; G Strauss; A Elias; Arthur T Skarin; Larry N Shulman; Marshall R Posner; Emil Frei
Phase II study of topotecan in metastatic non-small-cell lung cancer.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1994;12(2):347-52.
1994: C Epstein; Thomas J Lynch; J Shefner; P Wen; D Maxted; V Braman; P Ariniello; F Coral; Jerome Ritz
Use of the immunotoxin N901-blocked ricin in patients with small-cell lung cancer.
International journal of cancer. Supplement = Journal international du cancer. Supplement 1994;8():57-9.
1993: D H Kirn; Thomas J Lynch; Steven J Mentzer; T H Lee; Gary M Strauss; Anthony D Elias; Arthur T Skarin; David J Sugarbaker
Multimodality therapy of patients with stage IIIA, N2 non-small-cell lung cancer. Impact of preoperative chemotherapy on resectability and downstaging.
The Journal of thoracic and cardiovascular surgery 1993;106(4):696-702.
1993: David J Sugarbaker; Gary M Strauss; Thomas J Lynch; W Richards; Steven J Mentzer; T H Lee; J M Corson; Karen Antman
Node status has prognostic significance in the multimodality therapy of diffuse, malignant mesothelioma.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology 1993;11(6):1172-8.
1993: Thomas J Lynch; F Kass; L A Kalish; Anthony D Elias; G Strauss; Larry N Shulman; David J Sugarbaker; Arthur T Skarin; Emil Frei
Cisplatin, 5-fluorouracil, and etoposide for advanced non-small cell lung cancer.
Cancer 1993;71(10):2953-7.
1993: David J Sugarbaker; Steven J Mentzer; Malcolm M DeCamp; Thomas J Lynch; Gary M Strauss
Extrapleural pneumonectomy in the setting of a multimodality approach to malignant mesothelioma.
Chest 1993;103(4 Suppl):377S-381S.
1993: Thomas J Lynch
Immunotoxin therapy of small-cell lung cancer. N901-blocked ricin for relapsed small-cell lung cancer.
Chest 1993;103(4 Suppl):436S-439S.
1993: Thomas J Lynch
Management of malignant pleural effusions.
Chest 1993;103(4 Suppl):385S-389S.
1992: Thomas J Lynch; J R Clark; L A Kalish; B G Fallon; Anthony D Elias; Arthur T Skarin; Emil Frei
Continuous-infusion cisplatin, 5-fluorouracil, and bolus methotrexate in the treatment of advanced non-small cell lung cancer.
Cancer 1992;70(7):1880-5.